Stereotactic body radiotherapy(SBRT),also known as stereotatic ablative radiotherapy(SABR),is a non-invasive treatment method that can precisely delivery of ablation radiation dose.After decades of development and refinement,SBRT has been proved to be a safe and effective treatment for early stage non-small cell lung cancer(NSCLC).For patients with early-stage NSCLC who are ineligible or decline surgical intervention,SBRT has emerged as the standard treatment option.Additionally,for patients with early-stage NSCLC who cannot undergo pathological confirmation,SBRT is considered as one of the best choices.Despite the continuous advancements in clinical treatment with SBRT,numerous challenges remain.On one hand,to further enhance the local control rate(LCR)and pathologic complete response(pCR)rate among patients with early-stage NSCLC,scholars are actively exploring the potential of SBRT as a neoadjuvant therapy.On the other hand,despite the high LCR observed in patients with early-stage NSCLC after SBRT,distant metastasis remains a major issue affecting patient prognosis.Consequently,the combination of SBRT with systemic therapy has become a focal point of current research.Furthermore,the radiological changes observed in patients with early-stage NSCLC following SBRT have prompted new considerations in efficacy assessment and differential diagnosis.Therefore,this article delves into the international guidelines for the treatment of early-stage NSCLC,the current treatment landscape,and the clinical challenges and reflections faced,from both clinical and technical perspectives.

Stereotactic body radiotherapy(SBRT),also known as stereotatic ablative radiotherapy(SABR),is a non-invasive treatment method that can precisely delivery of ablation radiation dose.After decades of development and refinement,SBRT has been proved to be a safe and effective treatment for early stage non-small cell lung cancer(NSCLC).For patients with early-stage NSCLC who are ineligible or decline surgical intervention,SBRT has emerged as the standard treatment option.Additionally,for patients with early-stage NSCLC who cannot undergo pathological confirmation,SBRT is considered as one of the best choices.Despite the continuous advancements in clinical treatment with SBRT,numerous challenges remain.On one hand,to further enhance the local control rate(LCR)and pathologic complete response(pCR)rate among patients with early-stage NSCLC,scholars are actively exploring the potential of SBRT as a neoadjuvant therapy.On the other hand,despite the high LCR observed in patients with early-stage NSCLC after SBRT,distant metastasis remains a major issue affecting patient prognosis.Consequently,the combination of SBRT with systemic therapy has become a focal point of current research.Furthermore,the radiological changes observed in patients with early-stage NSCLC following SBRT have prompted new considerations in efficacy assessment and differential diagnosis.Therefore,this article delves into the international guidelines for the treatment of early-stage NSCLC,the current treatment landscape,and the clinical challenges and reflections faced,from both clinical and technical perspectives.

Cisplatin has good effects in the treatment of a variety of solid cancers.Studies have shown that cisplatin can make great contributions in treatment of nasopharyngeal carcinoma through DNA,telomeres,cell cycle,apoptosis,apoptotic volume decrease,cell senescence,NK cells and other channels.